SCHOTT Pharma
€24.55Change from previous close: +0.82%Absolute change: +€0.20
At a glance
- Revenue growth
- +3.04%
- FY to Sep 2025 vs FY to Sep 2024
- Net income growth
- −2.16%
- FY to Sep 2025 vs FY to Sep 2024
- Net margin
- 14.9%
- FY to Sep 2024: 15.6%
Financial data
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | FY to Sep 2025 | FY to Sep 2024 | FY to Sep 2023 | FY to Sep 2022 |
|---|---|---|---|---|
| Operating cash flow | 180 | 225 | 182 | 182 |
| Depreciation and amortization | 79.4 | 65.0 | 51.8 | 55.4 |
| Capital expenditure | -145 | -145 | -176 | -153 |
| Investing cash flow | -159 | -255 | -171 | -142 |
| Financing cash flow | -21.1 | 31.9 | -11.4 | -42.4 |
| Dividends paid | -24.1 | -22.6 | -18.9 | -11.5 |
| Debt issued | — | — | 0.0 | 0.0 |
| Debt repaid | — | 0.0 | -0.0 | 0.0 |
| Effect of exchange rates | -0.5 | -2.4 | -3.3 | 3.3 |
| Net change in cash | -0.2 | 1.2 | -1.2 | -2.4 |
| Free cash flow | 35.2 | 79.5 | 6.1 | 29.4 |